Walleye Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Walleye Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$126K	Sell	5,400 -8,300	-61%	-$180K	﹤0.01%	3572
2025 Q4	$288K	Sell	13,700 -5,100	-27%	-$89K	﹤0.01%	3346
2025 Q3	$289K	Sell	18,800 -10,800	-36%	-$141K	﹤0.01%	3036
2025 Q2	$277K	Buy	+29,600	New	+$326K	﹤0.01%	3110
2024 Q4	–	Sell	-1,000	Closed	-$19.3K	–	5511
2024 Q3	$19.3K	Buy	+1,000	New	+$20.7K	﹤0.01%	4820
2024 Q1	–	Sell	-4,100	Closed	-$88.6K	–	5863
2023 Q4	$88.6K	Buy	+4,100	New	+$63K	﹤0.01%	4100

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Walleye Capital's SNDX Position: Q1 2026 in Review

Walleye Capital increased its Syndax Pharmaceuticals (SNDX) stake by 1,490% in Q1 2026, buying an estimated $7.84M and bringing the position to 384,973 shares worth $8.99M. The position accounts for 0.04% of the portfolio, ranked #445.

Walleye Capital first reported a position in SNDX in Q4 2022 and has held it in 11 quarters since. The position peaked at $11.5M in Q1 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Walleye Capital held 384,973 shares of Syndax Pharmaceuticals worth $8.99M as of Q1 2026.
Walleye Capital bought 360,768 Syndax Pharmaceuticals shares in Q1 2026, an estimated $7.84M.
Syndax Pharmaceuticals made up 0.04% of Walleye Capital's portfolio in Q1 2026, its #445 holding.
Walleye Capital first reported a position in Syndax Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Walleye Capital's Syndax Pharmaceuticals position peaked at $11.5M in Q1 2023.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.